New treatment options before stem cell transplant for higher-risk MDS/AML
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 trial compares treatment approaches for people with higher-risk MDS or a specific type of AML before they get a stem cell transplant. The goal is to see which approach helps you get ready for transplant more safely and effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 and you have high-risk MDS or a related AML type with at least 5% blast cells in bone marrow
- Your bone marrow and risk scores meet the trial’s specific thresholds (including an IPSS intermediate/high score) and transplant is planned within 6 months
- Your activity level is good (ECOG 0 or 1) and you can sign informed consent
- Your heart function is strong enough (left heart pumping strength, LVEF, is at least 50%)
- Kidney, liver, and other key lab tests must be within allowed ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a less intense chemotherapy regimen to prepare patients with MDS for a stem cell transplant. It may be an option if you have intermediate or high-risk MDS and are between 14 and 70 years old.
This trial tests a new drug combination (SHR2554 and azacitidine) given before a stem cell transplant to treat aggressive leukemias, lymphomas, or bone marrow disorders. The goal is to improve survival and reduce cancer recurrence in patients with high-risk or hard-to-treat disease.
This trial tests a new drug combination (SHR2554 plus azacitidine) given before a stem cell transplant to treat aggressive leukemia, myelodysplastic syndrome, or lymphoblastic leukemia. The goal is to reduce cancer cells before transplant and improve outcomes.
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
This study tests whether CPX-351 can work better than standard intensive chemotherapy in adults with newly diagnosed AML that fits specific genetic patterns. It aims to improve how long patients stay in control of the leukemia.
This Phase 3 trial tests whether doing an “allogeneic” stem cell transplant works best for people newly diagnosed with higher-risk MDS (a bone marrow disorder). It’s mainly for patients who are healthy enough to receive a transplant and haven’t started MDS treatment yet.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.